Comparative developmental toxicities of the three major metabolites of N-methyl-2-pyrrolidone after oral administration in rats

Journal of Applied Toxicology

Volumn 27, Issue 6, 2007, Pages 571-581

  Saillenfait, A M ^a   Sabate J P ^a   Gallissot, F ^a  

^a INSTITUT NATIONAL DE RECHERCHE ET DE SÉCURITÉ   (France)

Author keywords

2 hydroxy N methylsuccinimide; 5 hydroxy N methyl 2 pyrrolidone; Developmental toxicity; Metabolites; N methyl 2 pyrrolidone; N methylsuccinimide; Rat

Indexed keywords

1 METHYL 2 PYRROLIDINONE; 2 HYDROXY N METHYLSUCCINIMIDE; 5 HYDROXY N METHYL 2 PYRROLIDINONE; DRUG METABOLITE; N METHYLSUCCINIMIDE; UNCLASSIFIED DRUG;

ANASARCA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOVASCULAR MALFORMATION; CONTROLLED STUDY; DIAPHRAGM HERNIA; EMBRYO DEVELOPMENT; FEMALE; FETUS; FETUS DEVELOPMENT; FETUS WEIGHT; FOOD INTAKE; GESTATIONAL AGE; INCIDENCE; INTESTINE INJURY; MATERNAL DISEASE; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; RAT; SKULL; TOXICITY; WEIGHT GAIN;

ABNORMALITIES, DRUG-INDUCED; ADMINISTRATION, ORAL; ANIMALS; BIOTRANSFORMATION; BODY WEIGHT; BONE AND BONES; CARDIOVASCULAR ABNORMALITIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; EMBRYONIC DEVELOPMENT; FEMALE; FETAL DEATH; FETAL WEIGHT; FETUS; GESTATIONAL AGE; HERNIA, DIAPHRAGMATIC; PREGNANCY; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; SOLVENTS; SUCCINIMIDES;

RATTUS;

EID: 36148987986     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1238     Document Type: Article

References (34)

1. Akesson B, Carnerup M, Jönsson B. 2004. Evaluation of exposure biomarkers from percutaneous absorption of N-methyl-2-pyrrolidone. Scand. J. Work Environ. Health 30: 306-312.
2. Akesson B, Jönsson BAG. 2000. Biological monitoring of N-methyl-2-pyrrolidone using 5-hydroxy-N-methyl-2-pyrrolidone in plasma and urine as the biomarker. Scand. J. Work Environ. Health 26: 213-218.
3. Akesson B, Paulsson K. 1997. Experimental exposure of male volunteers to N-methyl-2-pyrrolidone (NMP): acute effects and pharmacokinetics of NMP in plasma and urine. Occup. Environ. Med. 54: 236-240.
4. Angerer J, Bird MG, Burke TA, Doerrer NG, Needham L, Robison SH, Sheldon L, Zenick H. 2006. Strategic biomonitoring initiatives: Moving the science forward. Toxicol. Sci. 93: 3-10.
5. Anundi H, Langworth S, Johanson G, Lind ML, Akesson B, Friis L. 2000. Air and biological monitoring of solvent exposure during graffiti removal. Int. Arch. Occup. Environ. Health 73: 561-569.
6. Bader M, Keener SA, Wrbitzky R. 2005a. Dermal absorption and urinary elimination of N-methyl-2-pyrrolidone. Int. Arch. Occup. Environ. Health 78: 673-676.
7. Bader M, Rosenberger W, Rebe T, Keener SA, Brock TH, Hemmerling HJ, Wrbitzky R. 2005b. Ambient monitoring and biomonitoring of workers exposed to N-methyl-2-pyrrolidone in an industrial facility. Int. Arch. Occup. Environ. Health 79: 357-364.
8. Barrow MW, Taylor WJ. 1969. A rapid method for detecting malformations in rat fetuses. J. Morphol. 127: 291-306.
9. Becci PJ, Knickbockrer MJ, Reagan EC, Parent RA, Llewellyn WB. 1982. Teratogenicity study of N-methylpyrrolidone after dermal application to Sprague-Dawley rats. Fundam. Appl. Toxicol. 2: 73-76.
10. Bio-Research Laboratories Inc. 1990. An Oral Teratology Study of 2-Pyrrolidone in the Rat. Project # 83880. Sponsored by GAF Chemicals and BASF AG. UCLID dataset. http://ecb.jrc.it/
11. Bower DB. 1997. Letters to the editor: Stillbirth after occupational exposure to N-methyl-2-pyrrolidone. J. Occup. Environ. Med. 39: 393.
12. Carnerup MA, Saillenfait AM, Jönsson BAG. 2005. Concentrations of N-methyl-2-pyrrolidone (NMP) and its metabolites in plasma and urine following oral administration of NMP to rats. Food Chem. Toxicol. 43: 1441-1447.
13. Carnerup MA, Spanne M, Jönsson BAG. 2006. Levels of N-methyl-2-pyrrolidone (NMP) and its metabolites in plasma and urine from volunteers after experimental exposure to NMP in dry and humid air. Toxicol. Lett. 162: 139-145.
14. European Commission. 2005. Employment and Social Affairs. Health and Safety at Work. Provisional Statement of the Scientific Committee on Occupational Exposure Limits (SCOEL) on Occupational Exposure Limits for N-methyl-2-pyrrolidone. SCOEL/SUM/ 119-E.
15. Food and Drug Administration (FDA). Department of Health and Human Services. 2003. International conference on harmonisation; final recommendations on the revision of the permitted daily exposures for two solvents, N-methylpyrrolidone and tetrahydrofuran, according to the maintenance procedures for the guidance Q3C impurities: residual solvents; availability. Fed. Reg. 68/219: 64352-64353.
16. Hass U, Jakobsen BM, Lund SP. 1995. Developmental toxicity of inhaled N-methylpyrrolidone. Pharmacol. Toxicol. 76: 406-409.
17. Jönsson BAG, Akesson B, 2001. N-Methylsuccinimide in plasma and urine as a biomarker of exposure to N-methyl-2-pyrrolidone. Int. Arch. Occup. Environ. Health 74: 289-294.
18. Jönsson BAG, Akesson B. 2003. Human experimental exposure to N-methyl-2-pyrrolidone (NMP): toxicokinetics of NMP, 5-hydroxy-N-methyl-2-pyrrolidone, N-methylsuccinimide and 2-hydroxy-N-methylsuccinimide (2-HMSI), and biological monitoring using 2-HMSI as a biomarker. Int. Arch. Occup. Environ. Health 76: 267-274.
19. Keener SA, Wrbitzky R, Bader M. 2007. Human volunteer study on the influence of exposure duration and dilution of dermally applied N-methyl-2-pyrrolidone (NMP) on the urinary elimination of NMP metabolites. Int. Arch. Occup. Environ. Health 80: 327-334.
20. Klug S, Jaeckh R, Rossbacher R, Flick B. 2005. Assessment of in vitro toxicity of N-methyl-pyrrolidone and its metabolites using the whole embryo culture test. Naunyn Schmeidebergs Arch. Pharmakol. Exp. Pathol. 371 (Suppl 1): R125-R126.
21. Ligocka D, Lison D, Haufroid V. 2003. Contribution of CYP2E1 to N-methyl-2-pyrrolidone metabolism. Arch. Toxicol. 77: 261-266.
22. Office of Environmental Hazard Assessment. Reproductive and Cancer Hazard Assessment (OEHHA). 2003. Proposition 65 Maximum Allowable Dose Level (MADL) for Reproductive Toxicity for N-Methylpyrrolidone for Dermal and Inhalation Exposures.
23. 14C]methylpyrrolidone in male Sprague-Dawley rats. A saturable NMP elimination process. Drug Metab. Dispos. 30: 1418-1424.
24. Ravn-Jonsen A, Edelfors S, Hass U, Lund SP. 1992. The kinetic of N-methyl-2-pyrrolidone in pregnant rats and their foetuses compared with non-pregnant rats. Toxicol. Lett. Supp. 136: P5/P8.
25. Saillenfait AM, Gallissot F, Langonné I, Sabaté JP. 2002. Developmental toxicity of N-methyl-2-pyrrolidone administered orally to rats. Food Chem. Toxicol. 40: 1705-1712.
26. Saillenfait AM, Gallissot F, Morel G. 2003. Developmental toxicity of N-methyl-2-pyrrolidone in rats following inhalation exposure. Food Chem. Toxicol. 41: 583-588.
27. Saillenfait AM, Gallissot F, Sabaté JP. 2007 (in press). Developmental toxic effects of N-ethyl-2-pyrrolidone administered orally to rats. J. Appl. Toxicol. 27. DOI: 10.1002/jat1237.
28. Salewski E. 1964. Farbemethode zum makroskopischen Nachweis von Implantationsstellen am Uterus der Ratte. Naunyn Schmeidebergs Arch. Exp. Pathol. Pharmakol. 247: 367.
29. Sitarek K. 2003. Excretion and maternal-fetal distribution of N-methyl-2-pyrrolidone in rats. Reprod. Toxicol. 17: 505.
30. Solomon GM, Morse EP, Garbo MJ. 1997. The author reply. J. Occup. Environ. Med. 39: 394.
31. Solomon GM, Morse EP, Garbo MJ, Milton DK. 1996. Stillbirth after occupational exposure to N-methyl-2-pyrrolidone. J. Occup. Environ. Med. 38: 705-713.
32. Staples RE, Schnell VL. 1964. Refinements in rapid clearing technique in the KOH-Alizarin red S method for bone. Stain Technol. 39: 62-63.
33. Sullivan FM, McElhatton PR. 1977. A comparison of the teratogenic activity of the antiepileptic drugs carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin, and primidone in mice. Toxicol. Appl. Pharmacol. 40: 365-378.
34. Wilson JG. 1965. Methods for administering agents and detecting malformations in experimental animals. In Teratology: Principles and Techniques, Wilson JG, Warkany J (eds). University of Chicago Press: Chicago; 262-277.